Nature Communications (Feb 2022)
The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples
- James E. Barrett,
- Chiara Herzog,
- Allison Jones,
- Olivia C. Leavy,
- Iona Evans,
- Susanne Knapp,
- Daniel Reisel,
- Tatiana Nazarenko,
- Yoo-Na Kim,
- Dorella Franchi,
- Andy Ryan,
- Joanna Franks,
- Line Bjørge,
- Michal Zikan,
- David Cibula,
- Nadia Harbeck,
- Nicoletta Colombo,
- Frank Dudbridge,
- Louise Jones,
- Karin Sundström,
- Joakim Dillner,
- Angelique Flöter Rådestad,
- Kristina Gemzell-Danielsson,
- Nora Pashayan,
- Martin Widschwendter
Affiliations
- James E. Barrett
- European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck
- Chiara Herzog
- European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck
- Allison Jones
- Department of Women’s Cancer, University College London
- Olivia C. Leavy
- Department of Health Sciences, University of Leicester
- Iona Evans
- Department of Women’s Cancer, University College London
- Susanne Knapp
- Department of Women’s Cancer, University College London
- Daniel Reisel
- Department of Women’s Cancer, University College London
- Tatiana Nazarenko
- Department of Women’s Cancer, University College London
- Yoo-Na Kim
- European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck
- Dorella Franchi
- Istituto Europeo di Oncologia, IRCCS
- Andy Ryan
- Department of Women’s Cancer, University College London
- Joanna Franks
- Breast Service, University College London Hospital
- Line Bjørge
- Department of Obstetrics and Gynaecology, Haukeland University Hospital
- Michal Zikan
- Department of Gynecology and Obstetrics, First Faculty of Medicine, Charles University in Prague, University Hospital Bulovka
- David Cibula
- Gynaecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague
- Nadia Harbeck
- Breast Center, Department of Obstetrics and Gynecology, University of Munich (LMU)
- Nicoletta Colombo
- Istituto Europeo di Oncologia, IRCCS
- Frank Dudbridge
- Department of Health Sciences, University of Leicester
- Louise Jones
- Centre for Tumour Biology Department, Barts Cancer Institute, Queen Mary University of London
- Karin Sundström
- Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet
- Joakim Dillner
- Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet
- Angelique Flöter Rådestad
- Department of Women’s and Children’s Health, Karolinska Institutet and Karolinska University Hospital
- Kristina Gemzell-Danielsson
- Department of Women’s and Children’s Health, Karolinska Institutet and Karolinska University Hospital
- Nora Pashayan
- Department of Applied Health Research, University College London
- Martin Widschwendter
- European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck
- DOI
- https://doi.org/10.1038/s41467-021-27918-w
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Breast cancer is most commonly diagnosed via a needle biopsy. In this study, the authors show that cervical samples from women with breast cancer have a methylation signature different to that of healthy controls.
